The biography, medical writings and family lineages of Qilu medical masters in the Ming and Qing dynasties were collected and collated, so as to analyze their contributions to expounding acupuncture and moxibustion theories, practicing medical ethics and morals, and academic inheritance in later generations; as well as exploring the valuable guidance to clinical practice of modern acupuncture and moxibustion. ZHAI Liang, YUE Hanzhen, HUANG Yuanyu and LIU Kui were representatives of Qilu masters in the Ming and Qing dynasties. They showed their respects on classics with high inclusion, laid stress on elaboration and innovation in theories and practice of meridians, acupoints and acupuncture technique specially. Based on family heritage and apprenticeship, not only the academic school of acupuncture-moxibustion with regional characteristics had been cultivated, but also the important foundation been laid for the perfection of acupuncture-moxibustion diagnosis and treatment system in later generations. The integration of medical ethics and medical skills showed the spirit of "the benevolence of a doctor". These masters devoted themselves to the collation and research of medical books, collected the classics of medical masters, and wrote a number of easily-learned popular works for clinical application to benefit future generations.
Moxibustion/history* ; Humans ; China ; Acupuncture/education* ; Acupuncture Therapy/history* ; History, 20th Century ; History, 19th Century

Objective:This study aims to explore the issues of data property rights confirmation based on the original intent of intellectual property (IP) systems and the unique characteristics of data. It proposes potential strategies and solutions for establishing property rights over data and data-driven achievements.Methods:The study utilized a theoretical analysis to investigate the importance of confirming property rights for data and data-related achievements in the context of data sharing and transactions. The study proposd specific protection schemes for data property rights system, given the distinct nature of data compared to traditional " things, " and analyzed the applicability and limitations of traditional property including IP rights to data. Comparative analysis was used to compare data property rights registration and with the protection of copyrights, patent rights, and commercial secrets to Aggregate Data and their product. This study also summarized China′s strategies for promoting data as a factor of production through data property rights systems.Results:Data exhibited multidimensionality and copyability. It possessed characteristics of both " real property" and " personal property", and similarity to those of intellectual achievements. Copyright cannot protect the intrinsic value of the data. Patent rights were not applicable to Aggregate Data, but they cover data-driven research outcomes, including those involving data and algorithms. However, under the unified conditions for substantive examination of patents for authorization, patent examination should reflect the characteristics of the times for " prior art" and " ordinary technician". Data property right registration offers certain advantages in terms of protection, but measures should be taken to avoid excessive protection and abuse of the rights.Conclusions:Big data is not the object of data property rights. The multidimensionality of data determines the multidimensionality of the rights framework. The data rights system include three dimensions: personal data rights, aggregate data rights, and traditional IP rights related to data-driven innovation in conjunction with other technologies. The right to data property can be confirmed through categorical strategy. The traditional IP system can encompass data-driven innovation, and data control rights can provide a basis for data benefits and ensure the income rights of contributors during data sharing and transactions.

Objective To observe CT manifestations of Fitz-Hugh-Curtis syndrome(FHCS).Methods Data of 23 patients with FHCS were retrospectively analyzed,and non-enhanced and enhanced abdominal and pelvic CT manifestations were observed.Results All 23 cases were found with pelvic inflammation,peritonitis,perihepatic inflammation,as well as abdominal and pelvic adhesion.The main manifestations of pelvic inflammation included pelvic effusion(23/23,100％),inflammatory changes of uterus and accessories(17/23,73.91％),and the latter presented as tubal thickening(8/17,47.06％)or tubal cystic dilatation and effusion(9/17,52.94％),with ovarian enlargement(8/9,88.89％)or nodules on uterine surface(1/9,11.11％).The main CT manifestations of peritonitis were peritoneal thickening(23/23,100％)and peritoneal nodules(15/23,65.22％),of perihepatic inflammation were mainly liver capsule enhancement(23/23,100％),subcapsular transient perfusion abnormality(16/23,69.57％),perihepatic effusion(20/23,86.96％)and perihepatic"violin-string sign"(16/23,69.57％).No inflammation in the bare area of liver was noticed.Among 23 cases,3 cases(3/23,13.04％)complicated with mechanical ileus,19 cases(19/23,82.61％)were accompanied by mesenteric or retroperitoneal lymph nodes enlargement with uniform or circular enhancement.Conclusion The main CT manifestations of FHCS included pelvic inflammation,peritonitis,perihepatic inflammation,as well as abdominal and pelvic adhesion,having certain characteristics.

Objective:To investigate the effects of paclitaxel combined with Ipatasertib on the proliferation,migration and epitheli-al-mesenchymal transition(EMT)of oral squamous cell carcinoma(OSCC)SCC-9 cells in vitro.Methods:SCC-9 cells were treated with paclitaxel and Ipatasertib repectively and in combination.CCK-8 test and EdU assay were used to detect cell proliferation ca-pacity.Cellular migration was detected by Transwell and scratch method.The protein expressions of E-cad,N-cad,Vimentin,AKT and NF-κB were detected by Western blot.Results:Paclitaxel of 0.5-32 μmol/L combined with Ipatasertib of 2.5 μmol/L(IC50)showed synergistic inhibitory effect on the proliferation of SCC-9 cells,the combination of paclitaxel and ipatasertib more significantly inhibited the migration,down-regulated the protein expression of AKT,NF-κB,N-cad and Vimentin,and up-regulated the protein expression of E-cad.Conclusion:The combination of paclitaxel and Ipatasertib may have synergistic inhibitory effects on the prolif-eration,migration and EMT of OSCC cells,the function may be ralated with the inhibition of PI3K/AKT signaling pathway.

Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.

Objective:To investigate the efficacy and toxicity of blinatumomab in the first-line and second-line treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL).Methods:A multi-center retrospective cohort study was conducted to analyze clinical data from 323 pediatric B-ALL patients treated with blinatumomab across 14 hospitals in China from May 2021 to July 2023. Patients were divided into four groups based on the treatment phase and disease status when blinatumomab was used: relapsed/refractory group, post-consolidation minimal residual disease (MRD)-positive group, early MRD-positive group, and MRD-negative group. Blinatumomab for the relapsed/refractory group was considered as second-line treatment, while the other 3 groups as first-line treatment. The MRD negativity rate after treatment, the survival rates and the incidence of severe adverse events were compared across these groups. Patients who received blinatumomab for more than 7 days were included in the efficacy analysis. Survival analysis was performed using the Kaplan-Meier method, and Log-Rank test was used to compare the survival rates among groups.Results:Among the 323 patients, 191 (59.1%) were male, with the age of 6.2 (3.9, 10.5) years. There were 117 patients in the relapsed/refractory group, 62 cases in the post-consolidation MRD-positive group, 43 cases in the early MRD-positive group, and 101 cases in the MRD negative group. In the relapsed/refractory group, the complete remission rate and MRD negativity rate after one course of blinatumomab were 71.4% (35/49) and 81.5% (75/92) for the 49 children without complete remission and the 92 children with flow cytometry-positive MRD, respectively. In the post-consolidation MRD-positive group, the MRD negativity rates after one course of blinatumomab were 100.0% (27/27), 12/16 and 9/19 for patients with MRD positivity detected by flow cytometry, polymerase chain reaction and next-generation sequencing, respectively. In the early MRD-positive group, the MRD negativity rates were 96.7% (29/30) and 9/9 for flow cytometry and next-generation sequencing, respectively. The 2-year overall survival rate and event-free survival rate for the 319 children evaluable for efficacy were (90.6±1.7)% and (87.6±1.9)%, respectively, with the relapsed/refractory group showing significantly lower overall survival rates and event-free survival rate compared to the other groups ( χ2=21.40, 26.21,both P<0.001). Grade 3 or higher adverse events occurred in 128 cases (39.6%), with hematological toxicity observed in 101 cases, while cytokine release syndrome (CRS), infection, and neurotoxicity occurred in 11, 26 and 8 cases, respectively. In addition, there were statistically significant differences in the grade 3 or higher CRS among the four groups ( χ2=8.03, P<0.05). Conclusion:Blinatumomab can clear MRD more effectively and achieve superior survival outcomes when used as first-line treatment for pediatric B-ALL, with less CRS.

Objective:To explore the framework of data ethics, especially data ethics principles based on the purpose of data ethics, and analyze data ethics strategies in China.Methods:The methods involved analyzing data ethics and its control scope based on literatures. The applicability of basic ethical principles to data ethics was disscussed, along with the development of data ethics and ethics review practices in the health field. Efforts were made to explain data ethics principles within the framework of basic ethical principles. The data ethics and ethical review strategy of China were analyzed under existing laws, regulations, and relevant policies.Results:Data ethics govern activite involving data, algorithms, and the application of data and algorithms. The purpose of data ethics aligned with research ethics, and the diverse descriptions of data ethics principles reported could be encompassed within basic ethical principles. Data ethics and requirements of data ethical reviews in China were reflected in the laws and regulations related to data safety and research ethics.Conclusions:Basic ethical principles are universally applicable. Data and research ethics represent the application of these basic ethical principles within distinct domains, each with specific requirements. Data ethics necessitate a comprehensive review of scientific and technological activities pertaining to data, algorithms, and their interactions, addressing ethical governance as well as ethical considerations.

Objective:This study aimed to explore the challenges and issues arising from the factors that affect the governance and management of big data and artificial intelligence in medicine, and to establish a foundation for proposing solutions to these challenges and issues.Methods:We analyzed how big data and artificial intelligence influence different aspects of medical research by reviewing a range of literature. We proposed potential strategies to address the major challenges and issues associated with medical big data and artificial intelligence by analyzing their core elements and interrelationships.Results:The application of big data and artificial intelligence has significantly impacted the paradigms of medical research, drug development, clinical decision-making, and medical education. Two main aspects highlighted the challenges and issues related to governance and management arising from these advancements. The first involved ethical challenges stemming from data and algorithmic processes, including those related to artificial intelligence. A major concern was the potential bias in the algorithms, which can emerge during data collection, coding, and feedback. The second aspect focused on the governance and management elements of the data and stakeholders. Two key issues were the quality and integration efficiency of fundamental data, as well as property rights and intellectual property related to data, which currently lack a proper recognition system. This recognition was vital for distributing rights, interests, and responsibilities among stakeholders during data sharing and applications.Conclusion:Key issues regarding the governance and management of big data and artificial intelligence in medicine should be addressed. These include developing a framework for data ethics, including ethical review strategies and keypoints for medical artificial intelligence; establishing standards for data structure to enhance data quality and interactivity; and clarifying the principles of decisions on data ownership and intellectual property to distribute rights and interests.

This study established the HPLC fingerprints and a multi-component content determination method for Bidens pilosa var. radiata and B. pilosa and conducted comprehensive evaluation by integrating fingerprint similarity comparison, cluster analysis(CA), and principal component analysis(PCA), aiming to provide a reference for the establishment of quality standards for Bidentis Herba. HPLC was launched on an Agilent Poroshell 120 EC-C_(18) chromatographic column(4.6 mm×250 mm, 4 μm) by gradient elution with a mobile phase of 0.1% aqueous phosphoric acid-acetonitrile at a flow rate of 0.7 mL·min~(-1), detection wavelength of 270 nm, column temperature of 25 ℃, and an injection volume of 5 μL. The fingerprint similarity of 20 batches of Bidentis Herba ranged from 0.775 to 0.979. A total of 20 common peaks were identified, and seven components were confirmed through comparison with reference substances: neochlorogenic acid, chlorogenic acid, isochlorogenic acid A, isochlorogenic acid B, isochlorogenic acid C, rutin, and hyperoside. These seven components exhibited good linearity within the ranges of 3.4-67.4, 33.0-660.3, 26.6-531.2, 3.5-70.5, 6.2-124.9, 2.4-48.3, and 4.6-91.5 μg·mL~(-1), respectively, with correlation coefficients(r) greater than 0.999. The average recovery rates ranged from 96.47% to 104.6%. CA and PCA classified the 20 batches of Bidentis Herba into two categories. PCA yielded two principal components, with a cumulative variance contribution rate of 80.557%. The established HPLC fingerprints and multi-component content determination method are simple and accurate, providing a scientific basis for the quality control and quality standard formulation of Bidentis Herba.
Chromatography, High Pressure Liquid/methods* ; Drugs, Chinese Herbal/chemistry* ; Quality Control ; Chemometrics/methods* ; Bidens/chemistry* ; Principal Component Analysis

This study established the HPLC fingerprints, characteristic chromatograms, and a multi-component content determination method for Bidens bipinnata and B. biternata. The chemical pattern recognition analysis was then employed to clarify the characteristic indexes of quality differences between the two original plants of Bidentis Herba, providing a reference for establishing the quality standards of Bidentis Herba. HPLC was launched on an Agilent Poroshell 120 EC-C_(18) chromatographic column(4.6 mm×250 mm, 4 μm) by gradient elution with a mobile phase of 0.1% aqueous phosphoric acid-acetonitrile at a flow rate of 0.7 mL·min~(-1), detection wavelength of 270 nm, column temperature of 25 ℃, and an injection volume of 5 μL. The similarity between the fingerprints of 18 batches of Bidentis Herba samples and the common pattern(R) ranged from 0.572 to 0.933. A total of 23 chromatographic peaks were calibrated. Through comparison with the reference substances, six components(neochlorogenic acid, chlorogenic acid, isochlorogenic acid A, isochlorogenic acid B, rutin, and hyperoside) were identified and subjected to quantitative analysis. The characteristic fingerprints of B. bipinnata and B. biternata were calibrated with 20 and 17 characteristic peaks, respectively. Among them, peaks 8, 9, 22, and 23 were the characteristic peaks of B. bipinnata, and peak 7 was the characteristic peak of B. biternata, which can be used to distinguish the two original plants of Bidentis Herba. The relative standard deviation of the content of the above-mentioned six components ranged from 36% to 123%. The cluster analysis, principal component analysis, and orthogonal partial least squares-discriminant analysis(OPLS-DA) classified the 18 batches of Bidentis Herba samples into two categories. Additionally, through the analysis of variable importance in projection(VIP) under OPLS-DA, three characteristic indexes, rutin, isochlorogenic acid A, and isochlorogenic acid B, were identified. The analytical method established in this study can comprehensively evaluate the consistency of Bidentis Herba samples derived from different original plants, specifically identify the differential components between them, and effectively distinguish the two original plants of Bidentis Herba, providing a basis for the differentiation between different original plants and the quality control of Bidentis Herba.
Chromatography, High Pressure Liquid/methods* ; Drugs, Chinese Herbal/chemistry* ; Quality Control ; Bidens/chemistry*